Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATNM
stocks logo

ATNM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.190
-9.52%
--
--
-0.200
-60.78%
--
--
0.060
-127.27%
Estimates Revision
The market is revising No Change the revenue expectations for Actinium Pharmaceuticals, Inc. (ATNM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.23%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-8.23%
In Past 3 Month
Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.450
sliders
Low
4.00
Averages
4.50
High
5.00
Current: 1.450
sliders
Low
4.00
Averages
4.50
High
5.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-04-01
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-27
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-27
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-25
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-25
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-20
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-18
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-11
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-11
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Actinium Pharmaceuticals Inc (ATNM.A) is -2.84, compared to its 5-year average forward P/E of -5.01. For a more detailed relative valuation and DCF analysis to assess Actinium Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.01
Current PE
-2.84
Overvalued PE
-2.22
Undervalued PE
-7.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.75
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.14
Undervalued EV/EBITDA
-3.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
220.80
Current PS
0.00
Overvalued PS
658.60
Undervalued PS
-217.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ATNM News & Events

Events Timeline

(ET)
2025-12-01
08:50:00
Actinium Pharmaceuticals Unveils Preclinical Data for ATNM-400 in Breast Cancer
select
2025-10-27 (ET)
2025-10-27
07:12:59
Actinium Pharmaceuticals' ATNM-400 Demonstrates Enhanced Anti-Tumor Efficacy
select
2025-10-24 (ET)
2025-10-24
08:33:33
Actinium unveils preclinical findings for ATNM-400
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-04Newsfilter
Actinium Pharmaceuticals, Inc. to Showcase ATNM-400 Findings for Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Broadening Pan-Tumor Profile Across Three Solid Tumor Types

  • New Treatment for Resistant Cancers: Actinium Pharmaceuticals announced promising preclinical data for ATNM-400, an antibody radioconjugate showing anti-tumor activity in hormone-resistant and HER2-resistant breast cancer, as well as efficacy in prostate and non-small cell lung cancers.

  • Presentation at SABCS: The data will be presented at the 2025 San Antonio Breast Cancer Symposium, highlighting ATNM-400's potential to overcome resistance to standard therapies like tamoxifen and trastuzumab, and its ability to synergize with existing treatments.

  • Broad Indication Potential: ATNM-400 demonstrates best-in-class efficacy across multiple solid tumors, with significant opportunities in high-value markets, including prostate cancer and NSCLC, where it has shown superior activity compared to leading therapies.

  • Innovative Mechanism: Utilizing Actinium-225, ATNM-400 targets a disease-driving protein linked to poor prognosis, offering a novel approach that may improve outcomes for patients with difficult-to-treat cancers, addressing significant unmet clinical needs.

[object Object]
Preview
9.0
10-24Newsfilter
Actinium Pharmaceuticals Unveils New Findings Showcasing Strong and Lasting Effectiveness of ATNM-400, a Pioneering Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

  • ATNM-400 Overview: Actinium Pharmaceuticals' ATNM-400 is a first-in-class antibody radioconjugate targeting a non-PSMA antigen, demonstrating potent anti-tumor activity and prolonged survival in prostate cancer models resistant to standard therapies like enzalutamide and 177Lu-PSMA-617.

  • Efficacy and Resistance: Preclinical studies show that ATNM-400 outperforms existing treatments, achieving durable tumor control and complete regression in 40% of cases when combined with enzalutamide, highlighting its potential in overcoming treatment resistance.

  • Clinical Implications: The novel mechanism of ATNM-400 offers a promising alternative for patients with metastatic castration-resistant prostate cancer (mCRPC) who have limited options due to low or absent PSMA expression, addressing a significant unmet clinical need.

  • Future Directions: Actinium plans to explore ATNM-400's applications beyond prostate cancer, including non-small cell lung cancer (NSCLC), where it has shown potential to overcome resistance to existing therapies, further expanding its therapeutic impact.

[object Object]
Preview
9.0
10-14Newsfilter
Actinium Pharmaceuticals to Present Data on ATNM-400, a Novel Actinium-225 Radiotherapy for Multiple Tumors, in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments

  • ATNM-400 Overview: Actinium Pharmaceuticals is advancing ATNM-400, a first-in-class Actinium-225 radiotherapy candidate, showing promise in treating prostate and non-small cell lung cancer (NSCLC), addressing significant unmet clinical needs in these major cancer indications.

  • Preclinical Findings: New preclinical data indicate that ATNM-400 can overcome resistance to the EGFR inhibitor osimertinib in EGFR-mutated NSCLC, demonstrating potent anti-tumor activity and potential for improved patient outcomes in a challenging oncology setting.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Actinium Pharmaceuticals Inc (ATNM) stock price today?

The current price of ATNM is 1.45 USD — it has increased 0 % in the last trading day.

arrow icon

What is Actinium Pharmaceuticals Inc (ATNM)'s business?

Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

arrow icon

What is the price predicton of ATNM Stock?

Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Actinium Pharmaceuticals Inc (ATNM)'s revenue for the last quarter?

Actinium Pharmaceuticals Inc revenue for the last quarter amounts to 90.00K USD, decreased % YoY.

arrow icon

What is Actinium Pharmaceuticals Inc (ATNM)'s earnings per share (EPS) for the last quarter?

Actinium Pharmaceuticals Inc. EPS for the last quarter amounts to -0.16 USD, decreased -56.76 % YoY.

arrow icon

What changes have occurred in the market's expectations for Actinium Pharmaceuticals Inc (ATNM)'s fundamentals?

The market is revising No Change the revenue expectations for Actinium Pharmaceuticals, Inc. (ATNM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.23%.
arrow icon

How many employees does Actinium Pharmaceuticals Inc (ATNM). have?

Actinium Pharmaceuticals Inc (ATNM) has 37 emplpoyees as of December 05 2025.

arrow icon

What is Actinium Pharmaceuticals Inc (ATNM) market cap?

Today ATNM has the market capitalization of 45.23M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free